Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Back in August, I made the argument why now’s the right time to buy safe stocks . Just over a month later, this continues to be the case. The volatility and uncertainty that has rocked the stock market so far in 202...
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales and Marketing and Tony Marrs Sr. Vice President of Regulatory Affairs and Clinical Operati...
Generic drugmaker Amphastar Pharmaceuticals ( NASDAQ: AMPH ) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its New Drug Application ("NDA") for an Epinephrine injection marketed as a single dose pre-filled syringe. Epinephrine injection is use...
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 16, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application ("NDA") for Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled...
Despite posting topline and bottom-line beats with its Q2 2022 financials, Amphastar Pharmaceuticals ( NASDAQ: AMPH ) fell ~14% on Tuesday after the company disclosed the recent FDA rejections of marketing applications for two generic drugs. During the earnings cal...
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2022 Results Earnings Conference Call August 8, 2022, 05:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Chief Financial Officer, Treasurer, Executive Vice President of Fina...
Image source: The Motley Fool. Amphastar Pharmaceuticals (NASDAQ: AMPH) Q2 2022 Earnings Call Aug 08, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Amphastar Pharmaceuticals (AMPH) Q2 2022 Earnings Call Transcript...
Amphastar Pharmaceuticals press release ( NASDAQ: AMPH ): Q2 Non-GAAP EPS of $0.39 beats by $0.04 . Revenue of $123.47M (+21.5% Y/Y) beats by $5.59M . For further details see: Amphastar Pharmaceuticals Non-GAAP EPS of $0.39 beats by $0.04, revenue of $123...
Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2022. Second Qu...
Amphastar currently has seven drugs under development, two drugs awaiting launch, and a base of over nine FDA-approved products in production. With the recent approval of generic ganirelix and vasopressin, which have a TAM of $850 million, AMPH could nearly double its revenue by YE 20...
News, Short Squeeze, Breakout and More Instantly...
Amphastar Pharmaceuticals Inc. Company Name:
AMPH Stock Symbol:
NASDAQ Market:
Amphastar Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Complete Solaria Inc Com (CSLR) rose 58.5% to $1.775 on volume of 71,457,263 shares Senti Biosciences Inc. (SNTI) rose 55.1% to $0.428 on volume of 64,207,396 shares Golden Heaven Group Holdings Ltd. (GDHG) rose 13.3% to $0.1711 on vo...
2024-06-19 18:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...